% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Faehling:300363,
      author       = {M. Faehling and S. Fallscheer and B. Schwenk and H.
                      Seifarth and J. Sträter and C. Lengerke$^*$ and P.
                      Christopoulos},
      title        = {{T}rends in {O}verall {S}urvival in {L}ung {A}denocarcinoma
                      with {EFGR} {M}utation, {KRAS} {M}utation, or {N}o
                      {M}utation.},
      journal      = {Cancers},
      volume       = {17},
      number       = {7},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2025-00797},
      pages        = {1237},
      year         = {2025},
      abstract     = {Treatment of lung adenocarcinoma has changed and now
                      includes checkpoint inhibitors (CPIs) or, in the case of an
                      EGFR mutation, third-generation EGFR TKI osimertinib. Few
                      data compare the long-term overall survival (OS) of current
                      and historic subgroups.This real-world analysis (KOMPASS
                      study) included stage IV lung-adenocarcinoma patients with
                      either EGFR, KRAS, or no mutation. Patients were assigned to
                      the 'current' EGFR, KRAS, or no-mutation cohort if they had
                      mutation testing using NGS (n = 199; median date of
                      diagnosis 2021). If they had an EGFR PCR test only, they
                      were assigned to the 'historic' EGFR or no-mutation cohort
                      (n = 127; median date of diagnosis 2014).Both the current
                      and the historic EGFR cohorts had significantly longer OS
                      than the respective no-mutation cohorts (HR 0.58 and 0.60,
                      respectively). The current no-mutation and EGFR cohorts had
                      a strong trend to longer OS than the respective historic
                      cohorts. In the no-mutation cohorts, the improvement was due
                      to an increase in long-term survivors (HR 0.71), whereas in
                      the EGFR mutation cohorts, the median OS was improved
                      without long-term survivors (HR 0.70). The KRAS cohort
                      showed OS like the no-mutation cohort, with a plateau of
                      long-term survivors around $20\%.A$ comparison of our data
                      with that of the phase III trials KEYNOTE-189 and FLAURA
                      suggests that the improved outcomes are due to the use of
                      CPIs or osimertinib. The clinical trial results are well
                      translated into real-world clinical practice with comparable
                      OS. KRAS patients benefit from CPI treatment like
                      no-mutation patients.},
      keywords     = {EFGR (Other) / Exon 21 (Other) / G12D (Other) / KRAS
                      (Other) / check point inhibitor (Other) / lung cancer
                      (Other) / overall survival (Other) / real-world data
                      (Other)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40227775},
      doi          = {10.3390/cancers17071237},
      url          = {https://inrepo02.dkfz.de/record/300363},
}